Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12706756 | 1.00 | MAPT (0.62) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL12908208 | 1.00 | MAPT (0.62) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL12706755 | 1.00 | MAPT (0.62) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL12908203 | 1.00 | MAPT (0.62) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL928888 | 1.00 | MAPT (0.62) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL14270533 | 1.00 | MAPT (0.62) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL4135351 | 1.00 | MAPT (0.62) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL31451008 | 0.95 | MAPT (0.58) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL11695165 | 0.95 | MAPT (0.58) | MAPTPKMTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL15797827 | 0.94 | MAPT (0.56) | MAPTPKMTSHRMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-4074695-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2022-10-19 | — | — | EP | disclosed |
| US-11008596-B2 | Cytochrome P450 BM3 enzyme variants for preparation of cyclopropanes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190211367-A1 | VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-07-11 | — | — | US | disclosed |
| US-10208322-B2 | In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
| US-20170247725-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247725-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-08-31 | — | — | US | disclosed |
| US-5602267-A | Organometallic catalysts for epoxidizing prochiral olefins and a new class of amid-salicylidene ligands | HOECHST CELANESE (US) | 1997-02-11 | — | — | US | disclosed |
| US-5508458-A | USEFUL IN EPOXIDATION OF OLEFINS | HOECHST CELANESE CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5491266-A | REACTING CHIRAL COMPOUND IN PRESENCE OF OPTICALLY ACTIVE METAL-LIGAND COMPLEX | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1996-02-13 | — | — | US | disclosed |
| EP-0600020-B1 | ASYMMETRIC SYNTHESES | UNION CARBIDE CHEM PLASTIC (US) | 1996-01-31 | — | — | EP | disclosed |
| EP-0673381-A1 | HOMOGENEOUS BIMETALLIC HYDROFORMYLATION CATALYSTS AND PROCESSES UTILIZING THESE CATALYSTS FOR CONDUCTING HYDROFORMYLATION REACTIONS | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1995-09-27 | — | — | EP | disclosed |
| US-5360938-A | Metal ligand complex phosphite hydrogenation catalysts | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1994-11-01 | — | — | US | disclosed |
| WO-1994020510-A1 | HOMOGENEOUS BIMETALLIC HYDROFORMYLATION CATALYSTS AND PROCESSES UTILIZING THESE CATALYSTS FOR CONDUCTING HYDROFORMYLATION REACTIONS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1994-09-15 | — | — | WO | disclosed |
| EP-0600020-A1 | ASYMMETRIC SYNTHESES. | UNION CARBIDE CHEM PLASTIC (US) | 1994-06-08 | — | — | EP | disclosed |
| WO-1993003839-A1 | ASYMMETRIC SYNTHESES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| US-4016204-A | ISOMERIZING ETHYL-2-PHENYL-CYCLOPROPANE CARBOXYLATE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | MAPT 383/4885PKM 805/4885TSHR 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.